(ii) Apart from its effect on EGFR degradation, PI4KIIα inhibition directly interferes with the PI3K/AKT pathway, thus the combined inhibition of PI4KIIα and EGFR results in a triple anti-tumor effect (Fig. 6E). Here, EGFR is linked to neoplasm.